Literature DB >> 19340446

The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus.

Abdullah Ayçiçek1, Zafer Cetinkaya, Halil Kiyici, Fethullah Kenar, Gülşah Aşik, Nuri Kiraz.   

Abstract

The purpose of the study was to evaluate the effectiveness of caspofungin and voriconazole in the treatment of experimental Aspergillus otitis media in an experimental rabbit model. A total of 30 New Zealand white rabbits were divided into four treatment groups and one control group. The rabbits were immunosuppressed by cyclophosphamide and triamcinolone acetonide. The right ear of each rabbit was infected by an injection of the inoculum of 0.1 ml (8.6 x 103 CFU/0.1 ml) of Aspergillus fumigatus into the middle ear cavity. At 72 h after the inoculation, amphotericin B 1 mg/kg per day (n = 6), itraconazole 10 mg/kg per day (n = 6), voriconazole 10 mg/kg per day (n = 6) and caspofungin 5 mg/kg per day (n = 6) were injected to each treatment group. No antifungal drug was administered to the control group (n = 6). Clinical and histopathological examination scores and microbiological analysis of middle ear mucosa were compared.There was statistically significant difference in the clinical scores, histopathological scores, and mean CFU/g between the treatment and control groups (P < 0.05). There was no statistically significant difference among the treatment groups in the clinical and histopathological scores, whereas there was statistically significant difference in the mean CFU/g (P < 0.05). The mean CFU/g of amphotericin B and caspofungin groups were similar and both were lower than the itraconazole and voriconazole groups. Also, the mean CFU/g of voriconazole group was lower than the itraconazole group (P < 0.05). Caspofungin and voriconazole were demonstrated at least as effective as amphotericin B and itraconazole. We suggest that caspofungin and voriconazole may be considered for the treatment of fungal infection of the ear.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19340446     DOI: 10.1007/s00405-009-0963-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  28 in total

Review 1.  Advances and challenges in management of invasive mycoses.

Authors:  Thomas F Patterson
Journal:  Lancet       Date:  2005 Sep 17-23       Impact factor: 79.321

2.  Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; D Loebenberg; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Aspergillus mastoiditis in a patient with systemic lupus erythematosus: a case report.

Authors:  Kwamena Amonoo-Kuofi; Phillipa Tostevin; Jeff R Knight
Journal:  Skull Base       Date:  2005-05

4.  Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.

Authors:  M Boogaerts; D J Winston; E J Bow; G Garber; A C Reboli; A P Schwarer; N Novitzky; A Boehme; E Chwetzoff; K De Beule
Journal:  Ann Intern Med       Date:  2001-09-18       Impact factor: 25.391

5.  Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Randall A Prince; Jingduan Chi; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

6.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

Authors:  Thomas J Walsh; Hedy Teppler; Gerald R Donowitz; Johan A Maertens; Lindsey R Baden; Anna Dmoszynska; Oliver A Cornely; Michael R Bourque; Robert J Lupinacci; Carole A Sable; Ben E dePauw
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

7.  Amphotericin B: time for a new "gold standard".

Authors:  Luis Ostrosky-Zeichner; Kieren A Marr; John H Rex; Stuart H Cohen
Journal:  Clin Infect Dis       Date:  2003-07-22       Impact factor: 9.079

Review 8.  Caspofungin for treatment of invasive aspergillus infections.

Authors:  W J Heinz; H Einsele
Journal:  Mycoses       Date:  2008       Impact factor: 4.377

Review 9.  Recent advances and challenges in the treatment of invasive fungal infections.

Authors:  Pei-Lan Shao; Li-Min Huang; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2007-10-24       Impact factor: 5.283

Review 10.  Otitis caused by Scedosporium apiospermum in an immunocompetent child.

Authors:  H S Bhally; C Shields; S Y Lin; W G Merz
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2004-07       Impact factor: 1.675

View more
  1 in total

1.  Are systemic voriconazole and caspofungin ototoxic? An experimental study with rats.

Authors:  Emine Aydın; Filiz Aydoğan; Eren Taştan; Ayşe Iriz; Gökhan Karaca; Ilknur Haberal Can
Journal:  Clin Exp Otorhinolaryngol       Date:  2012-08-27       Impact factor: 3.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.